Mitochondrial Functions and Oxidative Stress in ALS Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00331812 |
Recruitment Status : Unknown
Verified January 2011 by University Hospital, Clermont-Ferrand.
Recruitment status was: Recruiting
First Posted : May 31, 2006
Last Update Posted : January 19, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Amyotrophic Lateral Sclerosis | Procedure: Mitochondrial functions and oxidative stress |
Study Type : | Observational |
Estimated Enrollment : | 40 participants |
Time Perspective: | Prospective |
Official Title: | Study of Mitochondrial Functions and Oxidative Stress in ALS Patients. |
Study Start Date : | February 2006 |
Estimated Study Completion Date : | February 2008 |

- relationship between these abnormalities and the metabolic status (hypermetabolism or normometabolism).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- male or female
- age > 30 years
- definite or probable ALS according to the El Escorial criteria, bulbar or spinal form, ALS diagnosis < 1 year and treatment by riluzole.
Exclusion Criteria:
- family history of ALS,
- oral, enteral or parenteral nutritional supply,
- vitamin or trace element supplementation
- confusing illness (cancer, diabetes, chronic infectious or inflammatory disease,thyroid disorders, recent surgery...),
- current tobacco use,
- alcoholism
- treatment by corticosteroids,
- diuretics,
- anorectics
- NSAIDs
- cytotoxics
- anticoagulants...

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331812
Contact: Corinne Bouteloup, Dr | (+33) 04 73 75 05 04 | cbouteloup@chu-clermontferrand.fr |
France | |
Clermont-Ferrand University Hospital | Recruiting |
Clermont-Ferrand, Auvergne, France, 63000 |
Principal Investigator: | Corinne Bouteloup, Dr | University Hospital, Clermont-Ferrand |
Responsible Party: | Dr Corinne BOUTELOUP, CHU Clermont-Ferrand |
ClinicalTrials.gov Identifier: | NCT00331812 |
Other Study ID Numbers: |
CHU63-0007 |
First Posted: | May 31, 2006 Key Record Dates |
Last Update Posted: | January 19, 2011 |
Last Verified: | January 2011 |
Hypermetabolism Mitochondrial abnormalities Oxidant/antioxidant status |
Motor Neuron Disease Amyotrophic Lateral Sclerosis Neurodegenerative Diseases Nervous System Diseases Neuromuscular Diseases |
Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |